Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.
P/E ratio for Hualan Biological Engineering Inc. (002007.SZ)
P/E ratio as of 2023: 27.25
According to Hualan Biological Engineering Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 27.25. At the end of 2022 the company had a P/E ratio of 38.36.
P/E ratio history for Hualan Biological Engineering Inc. from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 27.25 |
| 2022 | 38.36 |
| 2021 | 40.85 |
| 2020 | 47.61 |
| 2019 | 38.27 |
| 2018 | 24.40 |
| 2017 | 31.84 |
| 2016 | 42.60 |
| 2015 | 43.41 |
| 2014 | 35.93 |
| 2013 | 34.86 |
| 2012 | 40.42 |
| 2011 | 38.89 |
| 2010 | 45.54 |
| 2009 | 32.80 |
| 2008 | 45.31 |
| 2007 | 96.43 |
| 2006 | 44.45 |
| 2005 | 14.98 |
| 2004 | 14.74 |
| 2003 | 17.93 |
| 2002 | 22.05 |
| 2001 | 41.19 |